About
Adjuvance develops a semi-synthetic process to mass-produce a superior version of the QS21 vaccine adjuvant to improve vaccine efficacy where current adjuvants are limited by natural supply constraints.
Explore Adjuvance's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.